{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:53:25Z","timestamp":1789239205806,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T00:00:00Z","timestamp":1385424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s12032-013-0778-2","type":"journal-article","created":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T09:22:03Z","timestamp":1385371323000},"source":"Crossref","is-referenced-by-count":13,"title":["Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma"],"prefix":"10.1007","volume":"31","author":[{"given":"George","family":"Tsirakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parascevi","family":"Roussou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantina A.","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kolovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Vasilokonstantaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Miminas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Kyriakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alegakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Alexandrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,26]]},"reference":[{"key":"778_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-med-070209-175325","volume":"62","author":"J Laubach","year":"2011","unstructured":"Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med. 2011;62:249\u201364.","journal-title":"Annu Rev Med"},{"key":"778_CR2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12185-011-0963-z","volume":"94","author":"E Otjacques","year":"2011","unstructured":"Otjacques E, Binsfeld M, Noel A, Beguin Y, Cataldo D, Caers J. Biological aspects of angiogenesis in multiple myeloma. Int J Hematol. 2011;94:505\u201318.","journal-title":"Int J Hematol"},{"key":"778_CR3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.2010.32.5449","volume":"29","author":"E Terpos","year":"2011","unstructured":"Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol. 2011;29:1907\u201315.","journal-title":"J Clin Oncol"},{"key":"778_CR4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.seminhematol.2012.04.011","volume":"49","author":"YW Qiang","year":"2012","unstructured":"Qiang YW, Heuck CJ, Shaughnessy JD Jr, Barlogie B, Epstein J. Proteasome inhibitors and bone disease. Semin Hematol. 2012;49:243\u20138.","journal-title":"Semin Hematol"},{"key":"778_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","volume":"23","author":"GD Roodman","year":"2009","unstructured":"Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009;23:435\u201341.","journal-title":"Leukemia"},{"key":"778_CR6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/84209","volume":"2","author":"C Gerard","year":"2001","unstructured":"Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol. 2001;2:108\u201315.","journal-title":"Nat Immunol"},{"key":"778_CR7","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","volume":"96","author":"S Choi","year":"2000","unstructured":"Choi S, Cruz JC, Craig J, Anderson J, Roodman GD, Alsina M. Macrophage inflammatory protein (MIP)-1a is a potential osteoclast stimulatory factor in myeloma. Blood. 2000;96:671\u20135.","journal-title":"Blood"},{"key":"778_CR8","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","volume":"97","author":"JH Han","year":"2001","unstructured":"Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1a is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 2001;97:3349\u201353.","journal-title":"Blood"},{"key":"778_CR9","first-page":"399","volume":"76","author":"T Kukita","year":"1997","unstructured":"Kukita T, Nomiyama H, Ohmoto Y, Kukita A, Shuto T, Hotokebuchi T, Sugioka Y, Miura R, Iijima T. Macrophage inflammatory protein-1a; (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest. 1997;76:399\u2013406.","journal-title":"Lab Invest"},{"key":"778_CR10","first-page":"S81","volume":"28","author":"B Oyajobi","year":"2001","unstructured":"Oyajobi B, Williams PJ, Pulkrabek D, Franchin G, Sherry B, Mundy GR. In vivo osteoclastogenic effects of the CC chemokine, macrophage inflammatory protein (MIP)-1a (abstract). Bone. 2001;28:S81.","journal-title":"Bone"},{"key":"778_CR11","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","volume":"100","author":"M Abe","year":"2002","unstructured":"Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002;100:2195\u2013202.","journal-title":"Blood"},{"key":"778_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-002-0558-0","volume":"82","author":"MG Alexandrakis","year":"2003","unstructured":"Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol. 2003;82:19\u201323.","journal-title":"Ann Hematol"},{"key":"778_CR13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00277-009-0834-3","volume":"89","author":"L Pour","year":"2010","unstructured":"Pour L, Svachova H, Adam Z, Almasi M, Buresova L, Buchler T, Kovarova L, Nemec P, Penka M, Vorlicek J, Hajek R. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol. 2010;89:385\u20139.","journal-title":"Ann Hematol"},{"key":"778_CR14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.leu.2404067","volume":"20","author":"A Vacca","year":"2006","unstructured":"Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20:193\u20139.","journal-title":"Leukemia"},{"key":"778_CR15","first-page":"3111","volume":"6","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6:3111\u20136.","journal-title":"Clin Cancer Res"},{"key":"778_CR16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0145-2126(03)00261-3","volume":"28","author":"MG Alexandrakis","year":"2004","unstructured":"Alexandrakis MG, Passam FH, Sfiridaki K, Moschandrea J, Pappa C, Liapi D, Petreli E, Roussou P, Kyriakou DS. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk Res. 2004;28:259\u201366.","journal-title":"Leuk Res"},{"key":"778_CR17","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2008-02-133751","volume":"113","author":"H Chen","year":"2009","unstructured":"Chen H, Campbell RA, Chang Y, Li M, Wang CS, Li J, Sanchez E, Share M, Steinberg J, Berenson A, Shalitin D, Zeng Z, Gui D, Perez-Pinera P, Berenson RJ, Said J, Bonavida B, Deuel TF, Berenson JR. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor induced vasculogenesis. Blood. 2009;113:1992\u20132002.","journal-title":"Blood"},{"key":"778_CR18","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/leu.2009.130","volume":"23","author":"M Roussou","year":"2009","unstructured":"Roussou M, Tasidou A, Dimopoulos MA, Kastritis E, Migkou M, Christoulas D, Gavriatopoulou M, Zagouri F, Matsouka C, Anagnostou D, Terpos E. Increased expression of macrophage inflammatory protein-1a on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia. 2009;23:2177\u201381.","journal-title":"Leukemia"},{"key":"778_CR19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","volume":"123","author":"E Terpos","year":"2003","unstructured":"Terpos E, Politou M, Szydlo R, Goldman J, Apperley J, Rahemtulla A. Serum levels of macrophage inflammatory protein-1alpha (MIP-1a) correlate with the extent of disease and survival in patients with multiple myeloma. Br J Haematol. 2003;123:106\u20139.","journal-title":"Br J Haematol"},{"key":"778_CR20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2141.2004.04864.x","volume":"125","author":"T Hashimoto","year":"2004","unstructured":"Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol. 2004;125:38\u201341.","journal-title":"Br J Haematol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0778-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-013-0778-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-013-0778-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T15:44:01Z","timestamp":1597074241000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-013-0778-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,26]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s12032-013-0778-2","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,26]]},"article-number":"778"}}